Abstract Details

Title Recognition and Management of Duchenne Muscular Dystrophy: Knowledge and Behavior Changes from Continuing �鶹��ýӳ��

Topic Neuromuscular and Clinical Neurophysiology (EMG)

Presentation(s) Neuromuscular and Clinical Neurophysiology (EMG) Posters (7:00 AM-5:00 PM)

Poster/Presentation
Number 020

Objective To assess the influence of online continuing medical education (CME) in addressing clinician gaps on recognition, treatment, and interdisciplinary approach to Duchenne Muscular Dystrophy (DMD) management.

Background Clinicians lack experience with DMD and are challenged to recognize and diagnose DMD in a timely manner. Clinicians also lack training in the use and application of recent treatment advances in mutation-specific therapies. Clinicians must incorporate the subspecialities involved in DMD management and provide an interdisciplinary approach to patient care.

Design/Methods 2 x 1hr CME activities launched live-online in 2019, and remained on-demand through 2020. Knowledge and competence questions were administered pre-, immediate post-, and 2 mos. post-activity. Responses from learner polling, and 2 mos. follow-up surveys were also analyzed for engagement, lessons learned, and continuing gaps. McNemar tests compared matched pair responses (pre/post & pre/2mos) with Cohen’s d for effect size.

Results Final program results showed 61 of 1,422 learners completed questions from all 3 time points: 82% reported a positive impact on patient experience, and 84% reported a positive impact on clinical practice, with 92 qualitative write-in examples provided (e.g., early diagnosis and referral, use of newer therapies, improved patient satisfaction and hope, etc.). All 8 CME test questions reflected statistically significant improvements on DMD indicators, referral pathway, treatment choice and application, management of cardiac issues, and transition from pediatric to adult care, with an average 15% pre to post improvement. Questions posed by learners indicate interest in signs of DMD, interdisciplinary care, treatment choices, and associated comorbidities.

Conclusions Quantitative testing and surveying supported the positive impact of live-online CME focused on improving clinician knowledge of DMD and competency in its evolving treatment approaches. Ongoing education is advised on: combination therapies, corticosteroid treatments, management of comorbidities, genetic counseling, DMD characteristics, and setting up interdisciplinary care.

Authors/Disclosures
Carole Drexel (PlatformQ LLC) PRESENTER	Carole Drexel has nothing to disclose.
John Brandsema, MD (Children's Hospital of Philadelphia, Division of Neurology)	Dr. Brandsema has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Biogen. Dr. Brandsema has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Genentech. Dr. Brandsema has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for PTC Therapeutics. Dr. Brandsema has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Sarepta. Dr. Brandsema has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Novartis. Dr. Brandsema has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Argenx. Dr. Brandsema has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Janssen. Dr. Brandsema has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Dyne. Dr. Brandsema has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Takeda. Dr. Brandsema has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Scholar Rock. Dr. Brandsema has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Edgewise. Dr. Brandsema has received personal compensation in the range of $500-$4,999 for serving as an officer or member of the Board of Directors for CureSMA. The institution of Dr. Brandsema has received research support from Novartis. The institution of Dr. Brandsema has received research support from Biogen. The institution of Dr. Brandsema has received research support from Alexion. The institution of Dr. Brandsema has received research support from CSL Behring. The institution of Dr. Brandsema has received research support from Pfizer. The institution of Dr. Brandsema has received research support from PTC Therapeutics. The institution of Dr. Brandsema has received research support from Sarepta. The institution of Dr. Brandsema has received research support from Astellas. The institution of Dr. Brandsema has received research support from Fibrogen. The institution of Dr. Brandsema has received research support from Genentech. The institution of Dr. Brandsema has received research support from Janssen. The institution of Dr. Brandsema has received research support from Scholar Rock.
	No disclosure on file
	No disclosure on file